CJC-1295 vs Ipamorelin: Mechanisms, Evidence & 2026 Status

CJC-1295 and ipamorelin both raise growth hormone, but through different receptors. CJC-1295 is a long-acting analog of growth hormone–releasing hormone (GHRH) that acts on the pituitary GHRH receptor; ipamorelin is a five-amino-acid ghrelin-receptor (GHS-R1a) agonist that was described as the first selective GH secretagogue. Neither is FDA-approved, human data for each are limited to small early-phase studies, and the popular combination has not been tested in a published controlled trial.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

CJC-1295 vs Ipamorelin at a Glance

Two Different Levers on the Same Axis

Growth hormone release from the pituitary is governed by two stimulatory signals and one brake: GHRH from the hypothalamus, ghrelin (acting through GHS-R1a), and somatostatin. Stimulating the GHRH receptor and the ghrelin receptor together produces a larger GH response than either alone — a phenomenon called GHRH–GHRP synergy, which has been characterized in men using infused GHRH and GHRP-2 [1]. That physiology is the rationale for pairing a GHRH analog with a ghrelin mimetic.

CJC-1295: a GHRH analog built to last

Native GHRH is cleared within minutes. CJC-1295 was engineered to fix that: a modified GHRH(1–29) carrying a reactive "Drug Affinity Complex" (DAC) that bonds to circulating albumin after injection. Preclinical work identified it as a long-lasting GRF analog that activated the pituitary GRF receptor in rats [2]. In healthy adults, two randomized, placebo-controlled, double-blind ascending studies found sustained increases in GH and IGF-1, with an estimated half-life of 5.8–8.1 days and no serious adverse reactions reported in that short program [3]. A follow-up study showed that GH secretion remained pulsatile after CJC-1295: pulse frequency and size were unchanged while trough GH rose markedly [4].

Ipamorelin: a selective ghrelin mimetic

Ipamorelin was developed at Novo Nordisk from the GHRP series. In rat pituitary cells and in animal models it released GH with potency and efficacy similar to GHRP-6, and in swine it did not alter FSH, LH, prolactin or TSH — the basis for calling it the first selective GH secretagogue [5]. Its only substantial human trial was not for GH at all: a phase 2, multicenter, double-blind, placebo-controlled study in 114 patients after bowel resection tested ipamorelin for postoperative ileus. It was well tolerated, but there were no significant differences from placebo in the key efficacy analyses [6].

DAC vs No-DAC: Two Different Drugs Under One Name

"CJC-1295" is used loosely for two molecules:

• CJC-1295 with DAC — the albumin-binding compound studied in the published human trials [3][4]. Its long half-life produces a sustained rise in baseline GH.
• CJC-1295 without DAC — more accurately called modified GRF(1–29) or Mod GRF 1-29. It has the stabilizing amino-acid substitutions but no albumin-binding group, so it acts briefly, closer to native GHRH pulses.

The published human pharmacology belongs to the DAC version. Claims about "no-DAC CJC-1295" generally extrapolate from GHRH physiology rather than from dedicated trials. When reading a product label or a study, check which molecule is meant.

Why CJC-1295 and Ipamorelin Are Combined

The combination (CJC-1295 and ipamorelin) rests on three arguments: the two act on different receptors, GHRH-plus-GHRP stimulation is synergistic in human physiology studies [1], and ipamorelin's selectivity is thought to limit off-target hormonal effects. What is missing is a controlled trial of the pairing itself. A 2026 review of GH-axis "performance" peptides notes that agents such as CJC-1295 (with and without DAC) and ipamorelin are widely self-administered from research-compound sources, with reported adverse effects spanning endocrine and other systems, and stresses the gap between that use and the clinical evidence [7]. For the history of the pairing's popularity, see why CJC-1295/ipamorelin is popular; for body-composition data claims, see CJC-1295 and ipamorelin body composition data.

Safety Considerations

• CJC-1295. FDA's Category 2 summary cited serious adverse events associated with CJC-1295, including increased heart rate, and limited clinical data (FDA's Category 2 safety-risk summary). Because the DAC form acts for days, any adverse effect is not quickly reversible.
• Ipamorelin. The same FDA summary cites a report of serious adverse events, including a death, when ipamorelin was given intravenously in a gastric-motility study, and notes that its unnatural amino acids complicate characterization.

• Class effects of raising GH/IGF-1. A review of GH secretagogues found them generally well tolerated in available studies, with some concern for rising blood glucose through reduced insulin sensitivity, and noted that few long-term, rigorously controlled studies exist — including on cancer incidence and mortality [8]. Active malignancy is a standard reason for caution with any therapy that raises IGF-1.

Dosing and monitoring decisions belong to the prescriber; we do not publish them.

2026 Regulatory Status

Neither peptide is FDA-approved. FDA placed CJC-1295 in 503A Category 2 in September 2023; the nominations were later withdrawn, and FDA's categories list updated May 14, 2026 shows CJC-1295 in no category — not Category 1, not on the 503A Bulks List. Ipamorelin's 503A nomination was also withdrawn; FDA lists it in Category 2 under the separate 503B interim policy (FDA's Category 2 safety-risk summary). Neither was among the peptides voted on at the July 2026 PCAC. Because these positions can change, check the FDA Peptide Status Tracker before relying on any compounded source.

Both are prohibited at all times for tested athletes under the WADA Prohibited List (S2 growth hormone releasing factors).

How CJC-1295 Compares With Other GH Peptides

Ipamorelin is also commonly compared with sermorelin, an older GHRH analog — see sermorelin vs ipamorelin. For the one GHRH analog with FDA approval, see CJC-1295 vs tesamorelin for visceral fat. The library page for ipamorelin covers its pharmacology in more depth.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A partner pharmacies that together cover all 50 states and D.C.; prescribers can start at For Providers.

Frequently Asked Questions

What is the difference between CJC-1295 and ipamorelin?

CJC-1295 is a GHRH analog that acts on the pituitary GHRH receptor; the DAC version binds albumin and lasts for days. Ipamorelin is a short-acting pentapeptide that activates the ghrelin receptor. They raise GH through different pathways.

Why are CJC-1295 and ipamorelin taken together?

Stimulating the GHRH and ghrelin receptors at the same time produces a synergistic GH response in human physiology studies. That is the rationale for the pairing, but no published controlled trial has tested the CJC-1295/ipamorelin combination itself.

What does DAC mean in CJC-1295?

DAC stands for Drug Affinity Complex, a chemical group that bonds CJC-1295 to serum albumin and extends its half-life to roughly six to eight days in healthy adults. "CJC-1295 without DAC" is a different, short-acting molecule better called modified GRF(1–29).

Is CJC-1295 FDA approved?

No. CJC-1295 is not approved, and after its nominations were withdrawn it is no longer in any FDA 503A category, including Category 1. Check the FDA Peptide Status Tracker for current compounding status.

Is ipamorelin safe?

Ipamorelin was well tolerated in a phase 2 postoperative ileus trial, but long-term safety data do not exist. FDA's compounding safety summary cites serious adverse events, including a death, reported with intravenous use in a gastric-motility study.

Is ipamorelin banned by WADA?

Yes. WADA lists ipamorelin among prohibited growth hormone secretagogues and CJC-1295 among prohibited GHRH analogues, both banned at all times.

References

1. Veldhuis JD, et al. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-92. PubMed
2. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. PubMed
3. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
4. Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. PubMed
5. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PubMed
6. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PubMed
7. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed
8. Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PubMed